Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Kombo

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Cheminformatics|January 13, 2012
Making SharePoint® Chemically Aware™Kartik Tallapragada, Joseph Chewning, David Kombo, et al.
Journal of Medical Case Reports|July 27, 2022
Confirmed diagnosis of classic Wiskott-Aldrich syndrome in East Africa: a case reportMpokigwa Kiputa, Obrey Urio, Anna Maghembe, et al.
Journal of Medicinal Chemistry|July 17, 2012
Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disordersAnatoly A Mazurov, Lan Miao, Balwinder S Bhatti, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Cheminformatics|January 13, 2012
Making SharePoint® Chemically Aware™Kartik Tallapragada, Joseph Chewning, David Kombo, et al.
Journal of Medical Case Reports|July 27, 2022
Confirmed diagnosis of classic Wiskott-Aldrich syndrome in East Africa: a case reportMpokigwa Kiputa, Obrey Urio, Anna Maghembe, et al.
Journal of Medicinal Chemistry|July 17, 2012
Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disordersAnatoly A Mazurov, Lan Miao, Balwinder S Bhatti, et al.
Pageof 1